Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Copaxone in Percutaneously Accessible Tumors
NCT03982212Phase 1Unknown
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glatiramer acetate in cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), sponsored by University of Kansas Medical Center. Primary endpoint: Treatment Related Adverse Events or Treatment Related Serious Adverse Events at 6 weeks. Status: unknown.
02
Drugs
glatiramer acetate
03
Conditions
cutaneous squamous cell carcinoma (cSCC)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03982212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982212.